Lumendi wins FDA nod for DiLumen IS endoscopic scissors
Lumendi said today it won FDA 510(k) clearance for its DiLumen IS endolumenal interventional scissors, now indicated for cutting, dissecting and cauterizing tissue within the digestive tract during endoscopic procedures.
The Westport, Conn.-based company touted the sterile, single-use disposable, monopolar electrosurgical device as the fourth it’s developed, and said that it and its recently cleared DiLumen CT are intended to help improve access and therapy in the colon and reduce the need for surgical interventions.
The recently cleared C2 is a second-gen Endolumenal interventional platform designed to ensure com...
Source: Mass Device - May 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Endoscopic / Arthroscopic Food & Drug Administration (FDA) Regulatory/Compliance Lumendi Source Type: news
Bringing AI to Colorectal Cancer Screening
Freenome is looking to build a diagnostic test that can learn from its mistakes. The South San Francisco, CA- based company is using artificial intelligence to improve colorectal cancer screening.
To do this, Freenome has initiated AI-EMERGE, a clinical study for the AI-Genomics blood test, which will collect samples from up to 3,000 patients in the U.S. and Canada.
Freenome CEO, Gabe Otte said the infusion of AI is a natural step in the evolution of diagnostics that should have been taken years ago.
“If you look at the traditional molecular diagnostic tests that are out there – the PSA tests for example – you’ve s...
Source: MDDI - May 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: IVD Source Type: news
Blue dye tablet helps identify polyps during colonoscopy
(Digestive Disease Week) Ingestion of a blue dye tablet during bowel prep for colonoscopy could be a significant advance in the early detection of colorectal cancer (CRC). When used in conjunction with colonoscopy, the blue dye increased adenoma detection rate (ADR) by nearly 9 percent, according to a study scheduled for presentation at Digestive Disease Week ® (DDW) 2018. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 22, 2018 Category: Cancer & Oncology Source Type: news
Colon Polyp Type May Be Key to Cancer Risk
Their study of almost 16,000 patients who underwent colonoscopy found that the long-term risk for colon cancer was 2.5 times greater for those with advanced polyps, compared to people without such growths. (Source: WebMD Health)
Source: WebMD Health - May 16, 2018 Category: Consumer Health News Source Type: news
Colon Polyp Type May Be Key to Cancer Risk
Title: Colon Polyp Type May Be Key to Cancer RiskCategory: Health NewsCreated: 5/15/2018 12:00:00 AMLast Editorial Review: 5/16/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 16, 2018 Category: Cancer & Oncology Source Type: news
Colon Polyp Type May Be Key to Cancer Risk
(Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - May 16, 2018 Category: Cancer & Oncology Source Type: news
Colon Polyp Type May Be Key to Cancer Risk
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 15, 2018 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Preventive Medicine, News, Source Type: news
Colon Polyp Type May Be Key to Cancer Risk
TUESDAY, May 15, 2018 -- The type of colon polyp that ' s spotted during a colonoscopy may help predict the likelihood of colon cancer, new research shows.
These polyps -- also called adenomas -- can be labeled advanced or non-advanced, explained... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 15, 2018 Category: General Medicine Source Type: news
CRC Polyps May Allow for Immune Checkpoint Inhibitors in Premalignant Lesions
Colorectal carcinomas in LS patients appear in background of mismatch repair (MMR) deficiency, show a unique immune profile, and response to immunotherapy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news
Check-Cap closes $20m Series C
Check-Cap (NSDQ:CHEK) said yesterday it closed an offering of Series C shares and warrants, raising approximately $20.2 million in total.
In the offering, the Isfiya, Israel-based company floated approximately 3.2 million units for $5.50 per unit, with each unit in the offering consisting of a single ordinary share or ordinary share equivalent and a Series C warrant to purchase one ordinary share.
The offering also included an underwriter’s option for an additional 478,407 shares and Series C warrants to purchase up to 478,407 shares, which was exercised in full, Check-Cap said.
Proceeds from the round are slated to...
Source: Mass Device - May 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Funding Roundup Wall Street Beat Check-Cap Source Type: news
Olympus inks co-development deal with Ai4gi for AI-supported colonoscopy solution
Olympus (TYO:7733) said today it inked a co-development deal with artificial intelligence joint venture Ai4gi which will give Olympus exclusive rights to offer Ai4gi’s AI solution designed for clinical decision support during colonoscopy screening and surveillance procedures.
Ai4gi is a joint venture between Imagia and Satis Operations, Tokyo-based Olympus said. The company added that the co-development agreement is intended to improve clinical outcomes during colonoscopy procedures, reduce costs and improve quality of life for patients.
“Ai4gi’s solutions to early colon cancer recognition are going to b...
Source: Mass Device - May 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Software / IT ai4gi Olympus Source Type: news
Precancerous colon polyps in patients with Lynch syndrome exhibit immune activation
(University of Texas M. D. Anderson Cancer Center) Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation well before cancer development, according to research from The University of Texas MD Anderson Cancer Center. The preclinical research challenges traditional models of cancer immune activation and suggests immunotherapy may be useful for colorectal cancer prevention in certain high-risk groups. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2018 Category: Cancer & Oncology Source Type: news
Science Saturday: Identifying characteristics of colon polyps most likely to progress to cancer
Researchers at Mayo Clinic are closer to answering the question, why does one colon polyp transform to cancer while another seemingly identical polyp does not? A colon polyp is a small clump of cells that forms on the lining of the colon. While most colon polyps are harmless some can develop into colon cancer, which [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - March 31, 2018 Category: Research Source Type: news
